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Abstract
Introduction: Malignant peritoneal mesothelioma is a rare cancer with poor patient survival. Female gender has
been identified as a positive prognostic factor. Recently, it has been suggested that the expression of estrogen
receptor b in malignant mesothelioma leads to tumor suppression and a better prognosis.
Case presentation: We report the case of a 48-year-old Caucasian woman who is alive and disease-free seven
years after the initial diagnosis and treatment of malignant peritoneal mesothelioma.
Conclusion: This patient’s long survival may be attributable to a combination of factors, including minimal disease,
complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy plus the estrogen receptor b
positivity of the tumor.
Introduction
Peritoneal mesothelioma is a rare but fatal disease; the
incidence is approximately one per million, and perito-
neal mesothelioma accounts for about 20% to 30% of all
cases of mesothelioma [1]. Although asbestos has been
implicated as the main carcinogen [2,3], other factors
such as radiation, peritonitis and SV40 have all been
implicated [4].
Peritoneal mesothelioma progresses with unspecific
symptoms, and when presented, it is commonly in the
form of increased abdominal girth, pain and weight loss;
hence, diagnosis is late, with a poor prognosis. A num-
ber of therapeutic regimens have been used to improve
prognosis [5], and currently debulking surgery is fol-
lowed by hyperthermic intraperitoneal chemotherapy
(HIPEC). This has led to marked improvement in
patients who were once classified as preterminal [6].
The current median survival is around 10 months, and
relative five-year survival is in approximately 16% [7].
Hence, more information on the disease and more effec-
tive therapies are needed to improve prognosis.
Case presentation
A Caucasian women, now aged 48 years, presented her-
self at the age of 40 years with abdominal pain (four to
five days), a bad taste in her mouth and tiredness. She
had epigastric discomfort caused by abdominal disten-
sion for the past four to five years and had multiple
upper and lower gastrointestinal endoscopic examina-
tions. Her medical history involved obesity, treatment
for a blocked salivary duct, hypertension, endometriosis,
appendectomy, Bell’s palsy and hormone replacement
therapy. Recent laproscopic cholecystectomy showed
areas of abnormality, and a biopsy revealed the presence
of malignant mesothelioma of epithelial histology.
A computed tomography (CT) scan showed peritoneal
tumor, not widely spread with no parenchymal liver dis-
ease. There were no pleural nodules or fluid collection
along with the absence of metastasis. Disease volume as
determined by peritoneal cancer index was low. The
patient denied any exposure to asbestos.
Tumor markers such as CA125 appeared to be normal
and ranged from 7 to 11, which fell within the reference
range (0-35 IU/mL). Blood analysis revealed that the
patient had mild to moderate anemia with moderate
thrombocytosis.
Laparotomy with peritonectomy performed one month
later revealed the accumulation of ascitic fluid (four
litres) with no liver disease but some disease affecting
the diaphragm, small bowel, colon and uterus. Complete
cytoreduction was carried out, with preservation of the
spleen (minor diseased part removed). Similarly, disease
affecting the small bowel, mesentery and colon was also
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HIPEC was carried out with 50 mg/m
2 of cisplatin and
15 mg/m
2 of Adriamycin for 90 minutes at 41.5°C and
20 mg/m
2 (5 cycles) of paclitaxel, with insertion of a
peritoneal catheter and port. The patient refused post-
operative chemotherapy.
Macroscopic findings showed a peritoneal tumor
(multiple pieces of omentum 400 × 200 × 50 mm in
aggregates), and microscopic investigation showed some
areas of prominent papillary tumor on mesothelial
surface. Nuclear atypia varied from minimal to focally
moderate with nuclear membrane irregularities and ani-
sonucleosis. Mitosis was rare (<1/10 high-power field).
Further focal stromal invasion of small groups of cells
and single cells was seen in underlying fat with an
absence of desmoplastic response. Very rare psammoma
bodies were seen, and necrosis was absent in this sec-
tion. Atypical mesothelial proliferation was also seen in
all sections examined. Chronic inflammation was also
seen in the subserosal connective tissues. Although the
tumor was WDPM entering into differential diagnosis,
t h ee x t e n to ft h ed i s e a s ea n dt h ep r e s e n c eo fi n v a s i o n
mitigated against this diagnosis. The immunohistochem-
ical (ICH) findings are shown in Table 1.
Two years later, the patient presented herself with epi-
gastric discomfort, gastric reflux, abdominal pain, consti-
pation and diarrhea. A CT scan was normal, but the
patient underwent laparotomy and a second peritonect-
omy. The findings were adhesions (significant at term-
inal small bowel and right colon), few nodules (bowels
and mesentery) and a thin membranous septum on the
small bowel. Macroscopic examination showed occa-
sional atypical cells with minor peritoneal disease
(epitheloid cells) consistent with mesothelioma. There
was absence of tumor in lymph nodes, the lesser omen-
tum and the hepatic artery. Microscopic examination
results are shown in Table 2. Hence, it was concluded
that very low-volume disease was present, and pain was
mainly attributable to adhesions.
Treatment with HIPEC (cisplatin 200 mg + mitomycin
C 25 mg/90 min/41.5°C), extensive division of adhe-
sions, peritoneal biopsy and intraoperative ultrasonogra-
phy were carried out. The membranous septum on the
small bowel along with two nodules were also removed.
The patient refused to have postoperative chemotherapy.
Seven months later, the patient presented with a para-
spinal mass, and microscopic examination showed no
tumor; the patient was negative for CK5/6, cytokeratin
5.2, epithelial membrane antigen and mesothelial cell
membrane protein. Therefore, diagnosis was made in
favor of fibrosis and mild chronic inflammation.
Another 11 months later, the patient underwent laparot-
omy during which division of adhesions and repair of a
hernia was carried out. No evidence of mesothelioma
was found at this stage, and two months later, laparot-
omy was repeated for division of adhesions and debride-
ment of a large abscess owing to infection. The wound
did not heal, so the patient was prescribed antibiotic
therapy with an open wound-healing regimen. Finally,
the wound resolved, and currently the patient is well.
Discussion
Although the tumor was WDPM entering into differen-
tial diagnosis, the extent of the disease and the presence
of invasion mitigated against this diagnosis. Hence, the
patient underwent cytoreductive surgery with HIPEC,
which is most effective for patients with malignant peri-
toneal mesothelioma (MPM). Only two peritonectomies
with HIPEC were carried out in this patient, and she
did not receive postoperative chemotherapy. Although
the patient developed some complications as a result of
adhesions, this was rectified during recovery with subse-
quent laparotomy. CT scans and ICH findings showed
the absence of any malignancy after the second HIPEC.
Unlike many patients, who succumb to the disease
soon after treatment, this patient is alive and well past
seven years. Close scrutiny of the case seems to reveal
three salient features that may have contributed to this
person’s favorable prognosis. First, it appears from diag-
nosis (macroscopic and microscopic) that the patient
Table 1 Protein markers that have been identified by
immuno histochemistry in the patient tumor samples
Protein Markers Positive (+) Negative (-)
CAM5.2 +
Cytokeratin +
HBME-1 + (thick or membranous)
CD 15 -
BER-EPA -
CEA -
Human epithelial antigen -
EMA + (focal staining)
Table 2 Diagnostic findings from patient specimens
(formalin fixed and paraffin embedded)
Section Result of Examination
Formalin fixed Atypical epithelioid cells present
Higher nuclear:cytoplasmic ratio
Paraffin
embedded
Presence of nodules of cellular tumor
Positive for HBME-1 and EMA
Absence of tumor in lymph nodes
Adipose tissue, omentum: low-grade epithelioid
mesothelioma
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volume with no metastasis) that with complete cytore-
duction is probably more amenable to HIPEC. This con-
clusion has been derived because the patient responded
well to HIPEC treatment in the first three years, after
which her examination revealed abatement of the dis-
ease. Indeed, the last laparotomy performed did not
reveal any disease.
Second, the pathology report indicated that the patient
had an epithelioid type of MPM with abundant cellular
cytoplasm that is less aggressive and more amenable to
HIPEC compared with the sarcomatous or mixed type [8].
Finally, immunohistochemical examination of the
tumor tissues revealed that the patient has a high
expression of estrogen receptor b (ERb) (Figure 1). Very
recent studies by Pinton et al. [9] have indicated that
ERb expression in pleural mesothelioma has prognostic
significance and that high expression of these receptors
has endowed marked longevity in these patients. These
authors have also suggested that manipulation of ERb
receptors may offer a new mode of therapy for this type
of cancer. Our studies have also shown that the expres-
sion of ERb in peritoneal mesothelioma offers a better
prognosis (unpublished data).
Noticeably, this patient’s plasma estradiol was mea-
sured to be 483 rmol/L, which is comparable to levels
found in women during the follicular phase of the ovar-
ian cycle. Estradiol is a universal ligand for both ERa
and ERb.E R b is endowed with modulatory function on
ERa-dependant cell proliferation [10], and when present
by itself, it is able to control cell replication through the
G2-M phase cell arrest in a ligand-dependant and -inde-
pendent manner [9]. Hence, it may be suggested that
the high level of estradiol together with the high expres-
sion of ERb could have led to better disease control and
hence longer survival.
Conclusion
Taken as whole, cytoreduction with HIPEC has con-
ferred good prognosis on this patient owing to the mild
nature of the disease of epitheloid histology with ERb
expression and high plasma estradiol level.
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Written informed consent was obtained from the patient
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